Beacon Hospital Sdn Bhd
Petaling Jaya, Selangor, 46050, Malaysia
Location contact
Geeta Appanah, PhD
SUB_INVESTIGATOR
Mohd Hamzah Kamaruzaman, FRCS, Md
SUB_INVESTIGATOR
Sook Hui Tay
CONTACT
Syamimi Samah, PhD
SUB_INVESTIGATOR
NCT Number: NCT05882266
The goal of this clinical trial is to investigate the outcome of plant-based omega-3 intervention on lipid profile and blood pressure after 12 weeks and to study the molecular markers associated with the incidence of CVD risk. The main questions it aims to answer are:
* What is the role of plant-based omega-3 intervention on lipid profile and blood pressure of individuals with CVD risk after 12 weeks? * What is the association between unique molecular markers and plant-based omega-3 intervention among individuals with CVD risk?
Participants will be subjected to two groups:
* Treatment group: Receive standard dietary therapy and plant-based omega-3 supplemental beverage consumed once daily during breakfast * Control group: Receive only standard dietary therapy
Researcher will compare between treatment and control group to see the effect of plant based omega-3 on lipid profile and blood pressure after 12 weeks
Trial opening soon.
Get Notified18 year–60 year
All sexes
Interventional
Not applicable
Petaling Jaya, Selangor, 46050, Malaysia
Geeta Appanah, PhD
SUB_INVESTIGATOR
Mohd Hamzah Kamaruzaman, FRCS, Md
SUB_INVESTIGATOR
Sook Hui Tay
CONTACT
Syamimi Samah, PhD
SUB_INVESTIGATOR
This study is a single-blinded, randomised controlled, parallel clinical trial with the aim to compare the effect of plant-based omega-3 versus standard dietary therapy among individuals with CVD risk for 12 weeks. The randomisation will be done by an independent researcher.
Following, the sample size for this study is 72 individuals with CVD risk, calculated based from two previous studies that investigated the effect of plant based omega 3 intake on cardiometabolic risk individuals and dairy beverages intake among type 2 diabetes mellitus patient.
Besides that, demographic information, medical history, medication history, social history, family history and nutritional information will be gathered using the Case Report Form (CRF) along with 3 days diet record and International Physical Activity Questionnaire (IPAQ) for physical activities assessment. Furthermore, anthropometric data, pain assessment, product sensory evaluation and compliance assessment will also be assessed using the same CRF form.
Correspondingly, 10-hour fasting blood sample (20ml) will be collected from a total of 72 subjects (treatment group, n=36 and control group, n= 36, respectively) for the blood test profiles and genotyping microarray analysis. Subjects need to avoid any alcohol intake, unusual amounts of physical activity and unusual amounts of food intake within 24-hour of blood taking. All the biochemical analyses will be done and entirely sponsored by Beacon Precision Diagnostics Sdn. Bhd. The study will be conducted in compliance with ethical principles outlined in the Declaration of Helsinki and Malaysian Good Clinical Practice Guideline.
Also, subjects shall be informed of the study during their usual clinic visits. They will be requested to contact investigators if they are interested. An appointment will be made where the subject information sheet will be provided and explained to them. If they are willing to participate, the consent forms will be signed and dated. If they need to, they are allowed to take the information sheet home to consult with their family members and another day for getting consent arranged. This study is an independent study, subjects can choose to withdraw at any time. Lastly, the investigators declare they have no conflict of interest.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A commercial plant-based omega-3 beverage consumed once daily during breakfast
Standard dietary therapy
Time frame: Baseline and Week 12
Changes in the lipid profile level of LDL, HDL, total cholesterol, triglyceride using standard metric (mmol/L)
Time frame: Baseline and Week 12
Changes in both systolic and diastolic blood pressure using the standard unit (mmHg)
Time frame: Baseline and Week 12
Changes in microarray gene expression profile in blood from individual with CVD risk, in response to the 12 weeks intake of plant based omega 3
Time frame: Baseline, Week 12
Changes in high-sensitivity C-Reactive Protein (hs-CRP) using standard metric (mg/L)
Time frame: Baseline, Week 12
Changes in fasting blood glucose using standard metric (mmol/L)
Time frame: Baseline, Week 12
Changes in glycated hemoglobin (hbA1c) using standard metric (%)
Time frame: Baseline, Week 12
Changes in pain score assess using the short 0-10 numeric pain scale. It is a validated self-reported instrument assessing average pain intensity over the past 24 hour period. Possible scores range from 0 (no pain) to 10 (worst possible pain).
Contact information is provided by the study sponsor or research team.
Universiti Putra Malaysia
Other
The Role of Plant-Based Omega-3 Fatty Acids and Molecular Characterisation in Individuals With Cardiovascular(CVD) Risk at Beacon Hospital in Selangor
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07663201
Arrhythmias, Cardiac, Atrial Fibrillation
View Trial DetailsNCT07622394
Cancer Survivorship, Cancer Therapy-related Cardiac Dysfunction
Ürümqi, Xinjiang, China
View Trial DetailsNCT07589374
Arterial Stiffness, Blood Pressure Variability
São José do Rio Preto, São Paulo, Brazil
View Trial DetailsNCT07464184
Apnea, Autonomic Nervous System Dysfunction
Rouen, France
View Trial Details